90Y-Edotreotide (90Y-DOTATOC, 90Y-SMT487, 90Y-Onalta®, 90Y-OctreoTher®, 90Y-DOTA0-Phe1-Tyr3-Octreotide) is a drug patented by Novartis with rights owned by the German company ITM which actually develops the 177Lu-analogue. Despite the fact that ITM holds all the rights for the 90Y-labeled molecule as well, one should consider that, if not on hold, the molecule is at least considered as a second priority for them. The patent for the drug expired in September 2015 in Europe.
90Y-Edotreotide has demonstrated efficacy in patients with NET with partial and complete objective responses in up to 30% of patients. As for all other somatostatin radiolabeled analogues, the critical organ is the kidney followed by the bone marrow.
90Y-Edotreotide was the most advanced radiolabeled somatostatin analogue in clinical trial until it became obvious that 177Lu-labeled analogues would be more efficient. 90Y-Edotreotide has therefore been on hold since it completed Phase II trials in 2009.